Detalhe da pesquisa
1.
Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Nature
; 526(7572): 273-276, 2015 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26416749
2.
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Blood
; 125(20): 3133-43, 2015 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25833960
3.
Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.
Cancer Cell
; 8(1): 49-59, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16023598
4.
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Cancer Discov
; 13(3): 598-615, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511802
5.
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor.
J Med Chem
; 64(20): 15141-15169, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643390
6.
Real-time bioluminescence imaging of polycythemia vera development in mice.
Biochim Biophys Acta
; 1792(11): 1073-9, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19715759
7.
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Cancer Res
; 80(21): 4840-4853, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32928921
8.
Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells.
Clin Cancer Res
; 14(18): 5735-42, 2008 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18794082
9.
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
Cancer Res
; 67(5): 2081-8, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17332337
10.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Cancer Discov
; 9(12): 1696-1707, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31575541
11.
Rapid assembly of diverse and potent allosteric Akt inhibitors.
Bioorg Med Chem Lett
; 18(6): 2211-4, 2008 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18296048
12.
Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling.
Mol Cancer Ther
; 4(3): 413-25, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15767550
13.
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Cancer Immunol Res
; 4(2): 124-35, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26546453
14.
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Mol Cancer Ther
; 1(9): 747-58, 2002 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12479371
15.
[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments.
Transl Oncol
; 8(3): 147-53, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26055171
16.
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Cancer Discov
; 5(4): 424-37, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25776529
17.
Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
J Med Chem
; 46(14): 2973-84, 2003 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-12825937
18.
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.
J Med Chem
; 45(12): 2388-409, 2002 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-12036349
19.
A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
J Biomol Screen
; 8(4): 430-8, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-14567795
20.
High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.
Cancer Res
; 73(9): 2873-83, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23536552